Navigation Links
Syngenta Board Proposes Stefan Borgas to Become New Director
Date:2/25/2009

BASEL, Switzerland, Feb. 26 /PRNewswire-FirstCall/ -- Syngenta announced today that the Board of Directors will propose to shareholders at the Annual General Meeting on April 21, 2009, to name Stefan Borgas as a new member of the Syngenta Board.

Stefan Borgas (45) is Chief Executive Officer of Lonza, one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries, headquartered in Basel. Prior to joining Lonza in 2004 he worked in various senior international functions for BASF. Stefan Borgas holds a degree in business administration from the University of Saarbruecken, Germany, and an MBA from the University of St. Gallen, Switzerland.

Syngenta is one of the world's leading companies with more than 24,000 employees in over 90 countries dedicated to our purpose: Bringing plant potential to life. Through world-class science, global reach and commitment to our customers we help to increase crop productivity, protect the environment and improve health and quality of life. For more information about us please go to www.syngenta.com.

    Media contact:                Analyst/Investor contacts:

    Medard Schoenmaeckers         Jennifer Gough
    Switzerland   +41 61 323 2323 Switzerland   +41 61 323 5059
                                  USA           +1 202 737 6521

                                  John Hudson
                                  Switzerland   +41 61 323 6793
                                  USA           +1 202 737 6520

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements, which can be identified by terminology such as 'expect', 'would', 'will', 'potential', 'plans', 'prospects', 'estimated', 'aiming', 'on track' and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. We refer you to Syngenta's publicly available filings with the U.S. Securities and Exchange Commission for information about these and other risks and uncertainties. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. This document does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any ordinary shares in Syngenta AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on in connection with, any contract therefore.


'/>"/>
SOURCE Syngenta
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Syngenta Licenses Chromatin Gene Stacking Technology
2. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
3. Syngenta To Build Major Global Biotech Research Center in Beijing, China
4. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
5. Syngenta and Metabolon Inc. in Collaborative Research Agreement for Biochemical Profiling Technology
6. Syngenta Enters Into Research Collaboration With Anhui Academy, China
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. KGI Elects Three New Members to Board of Trustees
9. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
10. DOV Pharmaceutical, Inc. Begins Trading on OTC Bulletin Board
11. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... National Pharmaceutical Council (NPC) today announced that Ipsen Biopharmaceuticals, ... its newest member. David Cox , PhD, Vice ... ), will serve as his company,s representative on ... have Ipsen and Dr. Cox join NPC as members," ... their insights in helping us identify and address health ...
(Date:3/28/2017)... ... March 28, 2017 , ... LabKey and collaborator Just Biotherapeutics, ... solution, LabKey Biologics . Built in collaboration with Just and designed with ... provides drug research teams tools for biological entity registration, assay data integration, and ...
(Date:3/28/2017)... Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" or the ... from its phase 1/2 tendon repair study investigating the use ... a treatment for Achilles tendinosis. ... The clinical trial met its ... and showed no serious adverse events related to the study ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... to accelerating the fight against cancer, autoimmune disease and more through a single-cell ... single-cell metabolomics and proteomics analysis platform developed in the laboratory of Dr. ...
Breaking Biology Technology:
(Date:3/2/2017)... , March 2, 2017 Summary ... better understand Merck KGaA and its partnering interests and ... https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals and Alliance ... partnering activity of one of the world,s leading life ... prepared upon purchase to ensure inclusion of the most ...
(Date:3/2/2017)... , March 2, 2017 Australian stem ... (ASX: CYP), has signed an agreement with the ... the Monash Biomedicine Discovery Institute and Department of Pharmacology ... conduct a further preclinical study to support the use ... of asthma.  Asthma is a chronic, ...
(Date:2/28/2017)... --  Acuant , a leading provider of data capture ... new and core technologies building upon the acquisition of ... desktop Acuant FRM TM facial recognition and match ... manual review of identity documents by accredited professionals. ... most accurate capture software to streamline workflows by securely ...
Breaking Biology News(10 mins):